Sigilon Therapeutics, Inc.
DelistedCIK 1821323fmd_15HWNDBHSJD2ZWEP8S3XGVS63JManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2023, 14 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Total revenues | 13 | 10 | 13 |
| Research and development | 53 | 65 | 38 |
| Total operating expenses | 66 | 85 | 57 |
| Operating income | (53) | (76) | (44) |
| Interest expense | 1 | 2 | 2 |
| Interest and investment income | 0 | 0 | 1 |
| Other non-operating income (expense) | (2) | (2) | 0 |
| Income tax expense | 0 | 0 | 0 |
| Net income | (55) | (77) | (44) |
| Net income to common shareholders | (55) | (77) | (44) |